Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00237
|
|||||
| Drug Name |
Varenicline
|
|||||
| Synonyms |
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline; CP 526555; Champix (TN); Chantix (TN); Varenicline (INN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Smoking cessation [ICD11: 6C4A.2] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C13H13N3
|
|||||
| Canonical SMILES |
C1C2CNCC1C3=CC4=NC=CN=C4C=C23
|
|||||
| InChI |
InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+
|
|||||
| InChIKey |
JQSHBVHOMNKWFT-DTORHVGOSA-N
|
|||||
| CAS Number |
CAS 249296-44-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 211.26 | Topological Polar Surface Area | 37.8 | ||
| Heavy Atom Count | 16 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
0.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11056173
, 117645007
, 126616857
, 126649068
, 134337579
, 135659813
, 135724135
, 137001274
, 140812779
, 160964599
, 16411442
, 175265331
, 177748982
, 178102109
, 196106108
, 223736542
, 226504643
, 241376623
, 246170038
, 249738252
, 252157510
, 39340702
, 46505502
, 57359304
, 75856952
, 7978537
|
|||||
| ChEBI ID |
CHEBI:84500
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [3] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OCT-2 | Transporter Info | Km = 370 microM | Human embryonic kidney cells (HEK293)-OCT2 | [3] | |
| References | ||||||
| 1 | Varenicline was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. | |||||
| 3 | Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther. 2008 Apr;83(4):567-76. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.